Patent 11400132 was granted and assigned to Novaliq on August, 2022 by the United States Patent and Trademark Office.
The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutyl-pentane. The compositions may be used for topical administration to the eye.